HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 08, August 2017 – Eye – the Window to your Soul       » Palm-Sized PCR Device for Rapid Real-Time Detection of Viruses       » Scientists Uncover New Mechanism for Diabetic Neuropathy       » China Enlists AI to Diagnose Breast Cancer       » Philips and Singapore Institute of Advanced Medicine Holdings Sign Agreement to Open First-of-its-kind Oncology Center in Singapore       » Guardian Partners with MyDoc to Address Singapore's Population Health Needs through Integrating Technology and Self-Care       » Database Boosts Shanghai's Technology Aim      
BIOBOARD - CANADA
Genome British Columbia researchers closing in on chlamydia vaccine

Chlamydia is one of the most widespread sexually transmitted bacterial diseases in the world, causing an estimated 92 million infections globally per year. With existing treatment programs failing to stem the spread of infection, a vaccine is widely acknowledged as the only way to prevent the suffering and significant infertility caused by Chlamydia (C. trachomatis), the causative agent for the disease.

Recent advances in mass spectrometry technology, proteomics, genomics and Chlamydia immunology have resulted in significant advancements towards vaccine development. Through its Proof-of-Concept (POC) program Genome British Columbia (Genome BC) is funding the necessary pre-clinical studies to move a novel Chlamydia vaccine to human trials.

Genome British Columbia is a catalyst for the life sciences cluster on Canada's West Coast.

"Investment into public health is of significant importance to our province," says Dr. Alan Winter, President and CEO of Genome BC. "Genome BC remains committed to funding research that will result in practical, societal benefits and these projects demonstrate that."

Dr. Robert Brunham of the BC Centre for Disease Control is leading the POC project entitled "Accelerating the Development of a Novel Outer Membrane Protein Based Vaccine Against Chlamydia Infection". The project, in partnership with the Canadian not-for-profit Pan-Provincial Vaccine Enterprise Inc. (PREVENT), is expected to run over 21 months and will also include US Food and Drug Administration filings for anticipated clinical grade vaccine production.

The market profile for a Chlamydia vaccine is expected to be similar to the HPV vaccine currently on the market, which is now part of publicly funded healthcare and beginning to reduce HPV rates among Canadians.

Source: Marketwired News

Click here for the complete issue.

NEWS CRUNCH  
news Vitafoods Asia 2017 heralds a new future of innovation
news Sanner receives Zero Defect Award
news AdAlta pioneers novel drug for rare lung disease
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Advocacies in Support of Rare Disease Patients
July:
Food Science & Technology
August:
Eye – the Window to your Soul
September:
Emerging Infectious Diseases
October:
No. 1 Killer — Heart Diseases
November:
Diseases threatening our Children
December:
Skin Diseases/Allergic Reactions
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy